Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature reviews genetics

• Publication date

  2011-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrg2988PMID 21499295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy.

  2012cited by this paper
• State-of-the-art gene-based therapies: the road ahead

  2011cited by this paper
• Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.

  2011cited by this paper
• Current prospects for RNA interference-based therapies

  2011cited by this paper
• Hemophilia gene therapy: a Holy Grail found.

  2011cited by this paper
• Assessing the potential for AAV vector genotoxicity in a murine model.

  2011cited by this paper
• AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

  2011cited by this paper
• Ex vivo gene transfer and correction for cell-based therapies

  2011cited by this paper
• Adeno-Associated Virus Serotype 8 Gene Transfer Rescues a Neonatal Lethal Murine Model of Propionic Acidemia

  2011cited by this paper
• The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.

  2010cited by this paper
• CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.

  2010cited by this paper
• Liver-Directed Recombinant Adeno-Associated Viral Gene Delivery Rescues a Lethal Mouse Model of Methylmalonic Acidemia and Provides Long-Term Phenotypic Correction

  2010cited by this paper
• Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.

  2010cited by this paper
• Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

  2010cited by this paper
• Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

  2010cited by this paper
• Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

  2010cited by this paper
• Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B

  2010cited by this paper
• Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB).

  2010cited by this paper
• Directed Evolution of a Novel Adeno-associated Virus (AAV) Vector That Crosses the Seizure-compromised Blood-Brain Barrier (BBB).

  2010cited by this paper
• Newborn screening for treatable genetic conditions: past, present and future.

  2010cited by this paper
• Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs

  2010cited by this paper
• Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard Material

  2010cited by this paper
• Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice.

  2010cited by this paper
• Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study

  2010cited by this paper
• Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.

  2010cited by this paper
• Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle.

  2010cited by this paper
• Adeno-Associated Virus-Mediated Rhodopsin Replacement Provides Therapeutic Benefit in Mice with a Targeted Disruption of the Rhodopsin Gene

  2010cited by this paper
• Leber hereditary optic neuropathy gene therapy clinical trial recruitment: year 1.

  2010cited by this paper
• Dystrophin immunity in Duchenne's muscular dystrophy.

  2010cited by this paper
• Sustained alpha‐sarcoglycan gene expression after gene transfer in limb‐girdle muscular dystrophy, type 2D

  2010cited by this paper
• Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.

  2010cited by this paper
• Genome editing with engineered zinc finger nucleases

  2010cited by this paper
• Manufacturing and regulatory strategies for clinical AAV2-hRPE65.

  2010cited by this paper
• Efficient gene therapy-based method for the delivery of therapeutics to primate cortex

  2009cited by this paper
• Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.

  2009cited by this paper
• Host and vector-dependent effects on the risk of germline transmission of AAV vectors.

  2009cited by this paper
• Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy.

  2009cited by this paper
• Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

  2009cited by this paper
• Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

  2009cited by this paper
• Unique molecular signatures of disease brain endothelia provide a novel site for CNS-directed enzyme therapy

  2009cited by this paper
• Vision 1 year after gene therapy for Leber's congenital amaurosis.

  2009cited by this paper
• Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

  2009cited by this paper
• Investigation of the cause of death in a gene-therapy trial.

  2009cited by this paper
• Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.

  2009cited by this paper
• Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

  2009cited by this paper
• Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy

  2009cited by this paper
• Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons.

  2009cited by this paper
• Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates.

  2009cited by this paper
• Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes

  2009cited by this paper
• CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

  2009cited by this paper
• AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.

  2009cited by this paper
• Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteins

  2009cited by this paper
• Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy

  2009cited by this paper
• Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

  2009cited by this paper
• Cellular immune response to cryptic epitopes during therapeutic gene transfer

  2009cited by this paper
• Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration

  2009cited by this paper
• Persistent Expression of FLAG-tagged Micro dystrophin in Nonhuman Primates Following Intramuscular and Vascular Delivery

  2009cited by this paper
• Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial

  2008cited by this paper
• Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNA

  2008cited by this paper
• Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor α antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study

  2008cited by this paper
• Leber congenital amaurosis: genes, proteins and disease mechanisms.

  2008cited by this paper
• Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

  2008cited by this paper
• Manufacturing and characterizing AAV-based vectors for use in clinical studies

  2008cited by this paper
• Effect of gene therapy on visual function in Leber's congenital amaurosis.

  2008cited by this paper
• Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.

  2008cited by this paper
• Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

  2008cited by this paper
• Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.

  2008cited by this paper
• Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

  2008cited by this paper
• Safety and efficacy of gene transfer for Leber's congenital amaurosis.

  2008cited by this paper
• AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma

  2007cited by this paper
• Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.

  2007cited by this paper
• Cross-Presentation of Adeno-Associated Virus Serotype 2 Capsids Activates Cytotoxic T Cells But Does Not Render Hepatocytes Effective Cytolytic Targets

  2007cited by this paper
• Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.

  2007cited by this paper
• Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

  2007cited by this paper
• Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.

  2007cited by this paper
• Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.

  2007cited by this paper
• Adeno-Associated Virus Type 2 (AAV2) Capsid-Specific Cytotoxic T Lymphocytes Eliminate Only Vector-Transduced Cells Coexpressing the AAV2 Capsid In Vivo

  2007cited by this paper
• CD8+ T-cell responses to adeno-associated virus capsid in humans

  2007cited by this paper
• Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

  2007cited by this paper
• Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.

  2007cited by this paper
• Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial

  2007cited by this paper
• Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.

  2007cited by this paper
• Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.

  2006cited by this paper
• Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

  2006cited by this paper
• Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery.

  2006cited by this paper
• AAV8‐mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease

  2006cited by this paper
• Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia

  2006cited by this paper
• Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

  2006cited by this paper
• Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

  2006cited by this paper
• Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

  2006cited by this paper
• Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid

  2006cited by this paper
• Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.

  2006cited by this paper
• Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats.

  2006cited by this paper
• Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Serotype 2 α1-Antitrypsin (AAT) Vector in AAT-Deficient Adults

  2006cited by this paper
• Recombinant adeno-associated virus mediated gene transfer in a mouse model for homocystinuria

  2006cited by this paper
• Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors.

  2006cited by this paper
• Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno‐associated virus (rAAV1) vector

  2006cited by this paper
• Correction of Feline Lipoprotein Lipase Deficiency with Adeno-Associated Virus Serotype 1-Mediated Gene Transfer of the Lipoprotein Lipase S447X Beneficial Mutation

  2006cited by this paper
• Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice

  2006cited by this paper
• Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial.

  2006cited by this paper

• An SDS-NaOH-based method to isolate genome of recombinant adeno-associated virus vectors for physical titer measurement

  2025cites this paper
• Navigating molecular therapies: The emerging role of mRNA in treating inherited metabolic diseases.

  2025cites this paper
• An adeno-associated virus vector-based intracellular peptide delivery system for treating hepatocellular carcinoma with wild-type p53.

  2025cites this paper
• Optimized in vivo base editing restores auditory function in a DFNA15 mouse model

  2025cites this paper
• Subcutaneous administration of adipose-tropic gene therapy for congenital leptin deficiency

  2025cites this paper
• CRISPR-free RNA base editing mediated PTC-readthrough restores hearing in mice with Otof nonsense mutation

  2025cites this paper
• Therapeutic precision gene editing of cholesterol pathways as a gene therapy strategy for cardiovascular disease.

  2025cites this paper
• AAV2 delivery of the saCas9 gene results in presentation of an HLA-A∗02:01-restricted T cell epitope potent to induce T cell cytotoxicity

  2025cites this paper
• Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies

  2025cites this paper
• Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy.

  2025cites this paper
• Cell and gene therapeutic approaches in non-alcoholic fatty liver disease.

  2025cites this paper
• Emerging Technologies Tackling Adeno-Associated Viruses (AAV) Immunogenicity in Gene Therapy Applications

  2025cites this paper
• Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases

  2025cites this paper
• Editorial: Molecular mechanisms and treatment of monogenic skeletal disorders

  2025cites this paper
• Dose-finding and in vivo safety study of an adipose targeted leptin gene therapy for congenital leptin deficiency

  2025cites this paper
• Synthesis and DNA binding studies of pyrene-functionalized cationic block copolymer based on D-galactopyranose and 2-(dimethylamino)ethyl methacrylate

  2025cites this paper
• Retinal Epithelial Neutralization Assay Optimizes AAV Serotype Selection for Ocular Gene Therapy

  2025cites this paper
• Separation of empty and full adeno-associated viral capsids by MCSGP: From model-based design to implementation.

  2025cites this paper
• Gene Therapy in Rare Genetic Disorders: Current Progress and Future Perspectives

  2025cites this paper
• Mushrooms Lichens and Allopathic Medicine Principles and Performs

  2025cites this paper
• Mitochondrial diseases: from molecular mechanisms to therapeutic advances

  2025cites this paper
• New Insights into Genetic Right Ventricular Cardiomyopathies.

  2025cites this paper
• Advancing Therapeutics: CRISPR-Cas9 and Emerging Drug Delivery Systems

  2025cites this paper
• Current Trends in Gene Therapy to Treat Inherited Disorders of the Brain.

  2025cites this paper
• Regulatory Perspective for Biologics License Application of Recombinant Adeno-Associated Virus Products in China

  2025cites this paper
• Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders

  2025cites this paper
• Progress and prospect of minicircle as a minimized non-viral DNA vector in gene therapy and regenerative medicine

  2025cites this paper
• MiR‐146a Reduces Inflammation in Experimental Pancreatitis via the TRAF6–NF‐κB Signaling Pathway in Mice

  2025cites this paper
• Intelligent Hydrogel-Assisted Hepatocellular Carcinoma Therapy

  2024cites this paper
• A p21 reporter iPSC line for evaluating CRISPR-Cas9 and vector-induced stress responses

  2024cites this paper
• Therapeutic Gene Editing in Dyslipidemias

  2024cites this paper
• Development of an adipose-tropic AAV capsid ablating liver tropism

  2024cites this paper
• Adeno-Associated Viral Vectors in the Treatment of Epilepsy

  2024cites this paper
• In vivo neural regeneration via AAV-NeuroD1 gene delivery to astrocytes in neonatal hypoxic-ischemic brain injury

  2024cites this paper
• Publication trends of Leber congenital amaurosis researches: a bibliometric study during 2002-2022.

  2024cites this paper
• Chemical approaches to probe and engineer AAV vectors

  2024cites this paper
• Compact RNA editors with natural miniature Cas13j nucleases

  2024cites this paper
• AAV-DJ is superior to AAV9 for targeting brain and spinal cord, and de-targeting liver across multiple delivery routes in mice

  2024cites this paper
• Liposome-lentivirus for miRNA therapy with molecular mechanism study

  2024cites this paper
• Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems

  2024influential citation
• AAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation

  2024cites this paper
• Ultra-efficient delivery of CRISPR/Cas9 using ionic liquid conjugated polymers for genome editing-based tumor therapy.

  2024cites this paper
• Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights

  2024cites this paper
• Understanding AAV vector immunogenicity: from particle to patient

  2024cites this paper
• Breaking genetic shackles: The advance of base editing in genetic disorder treatment

  2024cites this paper
• Recent developments in gene therapy research in India

  2024cites this paper
• Post-polymerization functionalized sulfonium nanogels for gene delivery

  2024cites this paper
• Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice

  2024cites this paper
• Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies

  2024cites this paper
• In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model.

  2024cites this paper
• Peptide-based nanomaterials and their diverse applications.

  2024cites this paper
• Polyfunctional T cells and unique cytokine clusters imprint the anti rAAV2/rAAV9 vector immune response

  2024cites this paper
• Modulation of AAV9 Galactose Binding Yields Novel Gene Therapy Vectors and Predicts Cross-Species Differences in Glycan Avidity

  2024cites this paper
• Optimization of an adeno-associated viral vector for epidermal keratinocytes in vitro and in vivo

  2024cites this paper
• αFAP-specific nanobodies mediate a highly precise retargeting of modified AAV2 capsids thereby enabling specific transduction of tumor tissues

  2024cites this paper
• Limitation of Anion Exchange Chromatography and Potential Application of Hydrophobic Interaction Chromatography for Monitoring AAV9 Capsid Degradation Upon Thermal Stress.

  2024cites this paper
• Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson’s disease treatment

  2024cites this paper
• Targeted deletions in human mitochondrial DNA engineered by Type V CRISPR–Cas12a system

  2024cites this paper
• Targeted gene delivery systems for T-cell engineering

  2024cites this paper
• In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification

  2024cites this paper
• Promising tools for future drug discovery and development in antiarrhythmic therapy.

  2024cites this paper
• Electric pulse exposure reduces AAV8 dosage required to transduce HepG2 cells.

  2024cites this paper
• USE OF GENE THERAPY IN THE TREATMENT OF ALZHEIMER’S DISEASE – LITERATURE REVIEW

  2024cites this paper
• In the business of base editors: Evolution from bench to bedside

  2023cites this paper
• PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells

  2023cites this paper
• Semaphorin 4C regulates ovarian steroidogenesis through RHOA/ROCK1-mediated actin cytoskeleton rearrangement.

  2023cites this paper
• Rational design of immune gene therapy combinations via in vivo CRISPR activation screen of tumor microenvironment modulators

  2023cites this paper
• In situ-formable, dynamic crosslinked poly(ethylene glycol) carrier for localized adeno-associated virus infection and reduced off-target effects

  2023cites this paper
• Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans

  2023cites this paper
• Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer

  2023cites this paper
• Successful treatment of severe MSUD in Bckdhb−/− mice with neonatal AAV gene therapy

  2023cites this paper
• Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer

  2023cites this paper
• Biophysical characterization of adeno-associated virus capsid through the viral transduction life cycle

  2023cites this paper
• Acoustically Targeted Noninvasive Gene Therapy in Large Brain Regions

  2023cites this paper
• Nanobiomaterial vectors for improving gene editing and gene therapy

  2023cites this paper
• The Application of M 12L 24 Nanocages as Cell-Specific siRNA Delivery Agents in vitro

  2023cites this paper
• Intravenous AAV9 administration results in safe and widespread distribution of transgene in the brain of mini-pig

  2023cites this paper
• Current trends of clinical trials involving CRISPR/Cas systems

  2023cites this paper
• Rational immunosilencing of a promiscuous T-cell epitope in the capsid of an adeno-associated virus

  2023cites this paper
• Toward the quantification of adeno-associated virus titer by electrochemical impedance spectroscopy

  2023cites this paper
• Development of New Genome Editing Tools for the Treatment of Hyperlipidemia

  2023cites this paper
• Characterization and biodistribution of under-employed gene therapy vector AAV7

  2023cites this paper
• Precise Manipulation of the Site and Stoichiometry of Capsid Modification Enables Optimization of Functional Adeno-Associated Virus Conjugates.

  2023cites this paper
• Nebulized inhalation of LPAE-HDAC10 inhibits acetylation-mediated ROS/NF-κB pathway for silicosis treatment.

  2023cites this paper
• Advancements in Nipah virus treatment: Analysis of current progress in vaccines, antivirals, and therapeutics

  2023cites this paper
• Artificial Intelligence-Mediated Computer-Aided Design of Viral Gene Therapies

  2023cites this paper
• Biomaterial‐Based Gene Delivery to Central Nervous System Cells for the Treatment of Spinal Cord Injury

  2023cites this paper
• Precise manipulation of site and stoichiometry of capsid modification enables optimization of functional adeno-associated virus conjugates

  2023cites this paper
• Structure-guided AAV capsid evolution strategies for enhanced CNS gene delivery

  2023cites this paper
• Combining Surface-Induced Dissociation and Charge Detection Mass Spectrometry to Reveal the Native Topology of Heterogeneous Protein Complexes.

  2023cites this paper
• Prevention of Portal-Tract Fibrosis in Zfyve19−/− Mouse Model with Adeno-Associated Virus Vector Delivering ZFYVE19

  2023cites this paper
• A strategy for Cas13 miniaturization based on the structure and AlphaFold

  2023cites this paper
• RNA‐binding motif protein 24 inhibits HBV replication in vivo

  2023cites this paper
• MiR133b‐mediated inhibition of EGFR‐PTK pathway promotes rAAV2 transduction by facilitating intracellular trafficking and augmenting second‐strand synthesis

  2023cites this paper
• Sildenafil increases AAV9 transduction after a systemic administration and enhances AAV9-dystrophin therapeutic effect in mdx mice

  2023cites this paper
• Targeting of CRISPR-Cas12a crRNAs into human mitochondria.

  2023cites this paper
• Manuscript draft: Translatability barriers between preclinical and clinical trials of AAV gene therapy in inherited retinal diseases.

  2023cites this paper
• Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice

  2023cites this paper
• Enhancement of the liver’s neuroprotective role ameliorates traumatic brain injury pathology

  2023cites this paper
• Acoustically targeted noninvasive gene therapy in large brain volumes

  2023cites this paper